Kura Oncology Inc (NAS:KURA)
$ 21.2125 0.6025 (2.92%) Market Cap: 1.62 Bil Enterprise Value: 1.06 Bil PE Ratio: 0 PB Ratio: 3.20 GF Score: 36/100

Kura Oncology Inc at Citi Biotech Conference Transcript

Sep 05, 2019 / 01:30PM GMT
Release Date Price: $16.14 (+5.91%)
Yigal Dov Nochomovitz
Citigroup Inc, Research Division - Director

Session 2, focusing the laser on precision oncology. We had some companies yesterday on this theme, so this is our sequel. So it's my pleasure to introduce the Chief Executive Officers of Epizyme, Robert Bazemore; sitting over in the middle, from Kura, Troy Wilson, President and CEO; and to my right, Ali Tehrani, the CEO of Zymeworks.

So welcome all of you, thanks for taking the time. And just to start out, I think it would be helpful if each of you could give a quick 2- to 3-minute overview of your pipeline, your strategy, what are the key objectives for each of your companies.

Ali, you want to kick it off?

Ali Tehrani
Zymeworks Inc. - Co-Founder, President, CEO & Director

Sure. Thank you very much for organizing this conference and having us here. Zymeworks has focused on the research and development of multifunctional biologics. Currently, we have a number of bispecific antibodies in the clinic, our lead product is ZW25, which is a biparatopic antibody focused on HER2

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot